Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Basal-Type. We report the association of 80-GS reclassification wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitworth, Pat W., Beitsch, Peter D., Pellicane, James V., Baron, Paul L., Lee, Laura A., Dul, Carrie L., Murray, Mary K., Gittleman, Mark A., Budway, Raye J., Rahman, Rakhshanda Layeequr, Kelemen, Pond R., Dooley, William C., Rock, David T., Cowan, Kenneth H., Lesnikoski, Beth-Ann, Barone, Julie L., Ashikari, Andrew Y., Dupree, Beth B., Wang, Shiyu, Menicucci, Andrea R., Yoder, Erin B., Finn, Christine, Corcoran, Kate, Blumencranz, Lisa E., Audeh, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200401/
https://www.ncbi.nlm.nih.gov/pubmed/35476550
http://dx.doi.org/10.1200/PO.21.00463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200401/
https://www.ncbi.nlm.nih.gov/pubmed/35476550
http://dx.doi.org/10.1200/PO.21.00463

Ejemplares similares